In the start of the new year, the corona virus was controlled to a great extent, but now the situation has started deteriorating again. Meanwhile, Adar Poonawala, CEO of Serum Institute of India (SII), has given a sigh of relief. According to Poonawala, the trial of the new vaccine Covovax has started in India. It will also be produced by SII located in Pune.
Poonawala tweeted and wrote that the trial of Final Covovax has started in India. Novavax and Serum Institute are preparing this vaccine. It has also been tried on African and UK variants. Overall, it is up to 89 percent effective. Earlier it was expected that Novavax would launch the vaccine in the market by June, but on Saturday Poonawala said that it is expected to be launched by September 2021. However, this is the second vaccine of SII, which has been approved for trial by the Drug Controller General of India.
Prime Minister Narendra Modi started a vaccination campaign against the corona virus on 16th January.
Under this, the Covishield of SII and Bharat Biotech Covaxin are being installed. First of all, the Government of India administered vaccine doses to health workers and frontline workers. This was followed by the number of elderly and patients aged above 45 years of serious illnesses. Now from April 1, everyone above the age of 45 years will be vaccinated. With this, India has so far supplied millions of doses to other countries as well.